VPAResearch: Market Research Reports

Plague Pipeline Overview The Q4 Plague pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Plague, p...

Polio (Poliomyelitis) Pipeline Overview The Q4 Polio (Poliomyelitis) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...

Pompe Disease Pipeline Overview The Q4 Pompe Disease pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under develop...

Post Menopausal Osteoporosis Pipeline Overview The Q4 Post Menopausal Osteoporosis pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the p...

Progressive Multifocal Leukoencephalopathy Pipeline Overview The Q4 Progressive Multifocal Leukoencephalopathy pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterl...

Pyelonephritis Pipeline Overview The Q4 Pyelonephritis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...

Rabies Pipeline Overview The Q4 Rabies pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Rabies, p...

Ragweed Pollen Allergy Pipeline Overview The Q4 Ragweed Pollen Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs und...

Resistant Pseudomonas aeruginosa Infections Pipeline Overview The Q4 Resistant Pseudomonas aeruginosa Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarte...

Rhinovirus Infections Pipeline Overview The Q4 Rhinovirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...

Rotavirus Infections Pipeline Overview The Q4 Rotavirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs und...

Rubella (German Measles) Pipeline Overview The Q4 Rubella (German Measles) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of d...

Schistosomiasis Pipeline Overview The Q4 Schistosomiasis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under develop...

Severe Acute Respiratory Syndrome (SARS) Pipeline Overview The Q4 Severe Acute Respiratory Syndrome (SARS) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly re...

Sjogren Syndrome Pipeline Overview The Q4 Sjogren Syndrome pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under developme...

Smallpox Pipeline Overview The Q4 Smallpox pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Small...

Streptococcus pyogenes Infections Pipeline Overview The Q4 Streptococcus pyogenes Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes...

Tetanus Pipeline Overview The Q4 Tetanus pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Tetanus...

Tinea pedis (Athlete Foot) Pipeline Overview The Q4 Tinea pedis (Athlete Foot) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline...

Toxoplasmosis Pipeline Overview The Q4 Toxoplasmosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...

Tularaemia Pipeline Overview The Q4 Tularaemia pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for T...

Typhoid Fever Pipeline Overview The Q4 Typhoid Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...

Vancomycin-Resistant Enterococcus faecium Infections Pipeline Overview The Q4 Vancomycin-Resistant Enterococcus faecium Infections pipeline report is part of the VPA 110 Infectious Disease pipeline se...

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Pipeline Overview The Q4 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline report is part of the VPA 110 Infectious Dis...

Ventilator Associated Pneumonia (VAP) Pipeline Overview The Q4 Ventilator Associated Pneumonia (VAP) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review d...

Warts Pipeline Overview The Q4 Warts pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Warts, prov...

West Nile Virus Infections Pipeline Overview The Q4 West Nile Virus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline...

Western Equine Encephalitis Pipeline Overview The Q4 Western Equine Encephalitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipelin...

Yellow Fever Pipeline Overview The Q4 Yellow Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development f...

Report Description The September updated COVID-19 clinical trials report presents a comprehensive 1800 page analysis on all clinical trials across 96 countries worldwide. The report provides phase wis...

The September 2020 updated COVID-19 report identifies 440 companies investing in therapy and vaccination products. Around 24 companies have advanced their products into Phase 3 and around 15 companies...

COVID-19 Pipeline Analysis The September 2020 updated COVID-19 report identifies 440 companies investing in therapy and vaccination products. Around 24 companies have advanced their products into Phas...

2020 Acne Vulgaris PIPELINE HIGHLIGHTS Acne Vulgaris is one of the widely researched conditions during 2020 with 42 companies actively focusing on realizing pipeline’s potential. Development of Acne V...

2020 Acromegaly PIPELINE HIGHLIGHTS Acromegaly is one of the widely researched conditions during 2020 with 22 companies actively focusing on realizing pipeline’s potential. Development of Acromegaly m...

2020 Actinic Keratosis PIPELINE HIGHLIGHTS Actinic Keratosis is one of the widely researched conditions during 2020 with 10 companies actively focusing on realizing pipeline’s potential. Development o...

2020 Alcoholic Hepatitis PIPELINE HIGHLIGHTS Alcoholic Hepatitis is one of the widely researched conditions during 2020 with 14 companies actively focusing on realizing pipeline’s potential. Developme...

2020 Alopecia PIPELINE HIGHLIGHTS Alopecia is one of the widely researched conditions during 2020 with 40 companies actively focusing on realizing pipeline’s potential. Development of Alopecia medicin...

2020 Anemia in Chronic Kidney Disease PIPELINE HIGHLIGHTS Anemia in Chronic Kidney Disease is one of the widely researched conditions during 2020 with 25 companies actively focusing on realizing pipel...

2020 Angina (Angina Pectoris) PIPELINE HIGHLIGHTS Angina (Angina Pectoris) is one of the widely researched conditions during 2020 with 9 companies actively focusing on realizing pipeline’s potential....

2020 Aplastic Anemia PIPELINE HIGHLIGHTS Aplastic Anemia is one of the widely researched conditions during 2020 with 15 companies actively focusing on realizing pipeline’s potential. Development of Ap...

2020 Arrhythmias PIPELINE HIGHLIGHTS Arrhythmias is one of the widely researched conditions during 2020 with 15 companies actively focusing on realizing pipeline’s potential. Development of Arrhythmia...

2020 Arterial Thrombosis PIPELINE HIGHLIGHTS Arterial Thrombosis is one of the widely researched conditions during 2020 with 8 companies actively focusing on realizing pipeline’s potential. Developmen...

2020 Atrial Fibrillation PIPELINE HIGHLIGHTS Atrial Fibrillation is one of the widely researched conditions during 2020 with 23 companies actively focusing on realizing pipeline’s potential. Developme...

2020 Atypical Hemolytic Uremic Syndrome PIPELINE HIGHLIGHTS Atypical Hemolytic Uremic Syndrome is one of the widely researched conditions during 2020 with 9 companies actively focusing on realizing pi...

2020 Axillary Hyperhidrosis PIPELINE HIGHLIGHTS Axillary Hyperhidrosis is one of the widely researched conditions during 2020 with 7 companies actively focusing on realizing pipeline’s potential. Deve...

2020 Behcet Disease PIPELINE HIGHLIGHTS Behcet Disease is one of the widely researched conditions during 2020 with 8 companies actively focusing on realizing pipeline’s potential. Development of Behce...

2020 Bullous Pemphigoid PIPELINE HIGHLIGHTS Bullous Pemphigoid is one of the widely researched conditions during 2020 with 10 companies actively focusing on realizing pipeline’s potential. Development...

2020 Burns PIPELINE HIGHLIGHTS Burns is one of the widely researched conditions during 2020 with 32 companies actively focusing on realizing pipeline’s potential. Development of Burns medicines is ide...

2020 Celiac Disease PIPELINE HIGHLIGHTS Celiac Disease is one of the widely researched conditions during 2020 with 19 companies actively focusing on realizing pipeline’s potential. Development of Celi...

2020 Colitis PIPELINE HIGHLIGHTS Colitis is one of the widely researched conditions during 2020 with 27 companies actively focusing on realizing pipeline’s potential. Development of Colitis medicines...